SK CDM-QIP Diabetes + Heart Failure Flow Sheet

Type of Diabetes: ☐ Type 1 ☐ Type 2 ☐ Other			Patient Name:				
Date Diagnosed/Duration of DM:			Date of Blath.				
Type of Heart Failure:			Date of Birth:				
☐ HFrEF	(reduced ejection fraction LVEF ≤ 40%)			HSN:			
☐ HFpEf	(preserved ejection fraction LVEF ≥ 50%)			11514.			
	EF (minimally reduced ejection fraction LVEF 41						
	HF diagnosis: (Echo L	VEF	%)				
	omorbidities:				.	- 4	
	tage \square Hypert all health condition	ension	☐ Dyslipidemia	ı	AF 🗆 OS	οA	
	lar heart disease \Box Cardiomyop	athy	☐ Congenital hea	rt 🗆	Pacemaker		
vaivai		Date:	congenitar nea	Date:	Tacemaker	Date:	
Subject	ive	- Jute.		2410.		2410.	
Jubject							
	A1c (target ≤ 7% or)	Result	Test Date	Result	Test Date	Result	Test Date
	Glycemic Therapy/Medications						
ent							
au l	Adhayana /aanaayaa						
Glycemic Management	Adherence/concerns						
Mar	Review glucose records						
J ji	neview gracese receives						
cen	Hypoglycemic episodes						
Glý	Consider frequency, severity; provide educational resources						
	DM and driving discussed						
	SGI medical reporting form if using insulin						
	Sick day management reviewed						
	Consider SADMANS, other patient handouts						
~*	New or change in CVD and/or HF	□No		□ No		□No	
JS &	symptoms	☐ Yes:		☐ Yes:		☐ Yes:	
ton /	(angina/chest pain, edema, exertional dyspnea, decreased exercise tolerance, orthopnea/PND,						
Cardiac Symptoms & Stability	palpitations, increased diuretic use, claudication)						
	NYHA Functional Class	☐ class I		☐ class I		☐ class I	
liac S	Class I: HF symptoms only at levels of exertion that would	class II		☐ class II		☐ class II	
arc	limit normal individuals Class II: HF symptoms with ordinary exertion	☐ class III		☐ class III		☐ class III	
Ü	Class III: HF symptoms with less than ordinary exertion Class IV: HF symptoms at rest	☐ class IV		☐ class IV		☐ class IV	
	Is patient experiencing low	☐ Yes ☐	No 🗌 Not asked	☐ Yes ☐ N	No Not asked	☐ Yes ☐ No	☐ Not asked
ial	mood/anhedonia/anxiety?	Comment	ts:	Comment	s:	Comments:	
)80((Consider use of PHQ-9, GAD-7)						
Psychosocial review							
Psy. revi							







		Date:	Date:	Date:
Lifestyle	Nutrition/diet review (Intake of sodium, alcohol, other fluids)			
	Physical activity (consider referral to cardiac rehab if available)			
	Smoking status	☐ Non-smoker ☐ Ex-smoker ☐ Smoker	☐ Non-smoker ☐ Ex-smoker ☐ Smoker	☐ Non-smoker ☐ Ex-smoker ☐ Smoker
	Smoking cessation advice (if required)	☐ Yes ☐ No	☐ Yes ☐ No	☐ Yes ☐ No
Investigations	ECG (Baseline resting ECG at diagnosis, repeat every 1- 2 years if stable, more frequent if change in CV symptoms)	☐ Ordered today ☐ Up to date	☐ Ordered today ☐ Up to date	☐ Ordered today ☐ Up to date
	Echocardiography (At diagnosis; then about every 3 years if stable; more frequent if change in clinical status)			
	Lipid profile — LDL, non-HDL (non-fasting lipid profile recommended annually; treatment target is LDL-Chol < 2 mmol/ L or >50% reduction from baseline; alternate target non-HDL < 2.6 mmol/ L)	Result Test Date LDL Non-HDL	Result Test Date LDL Non-HDL	Result Test Date LDL Non-HDL
	Renal function and Lytes (Monitor as needed to ensure stability; adjust prescriptions; consider changes to diet/potassium intake if hyperkalemia)			
	Screen for OSA (Recommended annually; use STOP-BANG questionnaire and sleep study if indicated. Untreated OSA negatively impacts management of COPD and quality of life)	☐ reviewed risk factors/screened ☐ referred for sleep study ☐ known OSA diagnosis	☐ reviewed risk factors/screened ☐ referred for sleep study ☐ known OSA diagnosis	☐ reviewed risk factors/screened ☐ referred for sleep study ☐ known OSA diagnosis
_	Urine ACR (normal < 2 mg/mmol) (not required if eGFR < 15 mL/min)	Result Test Date	Result Test Date	Result Test Date
pathy	Serum creatinine	Result Test Date	Result Test Date	Result Test Date
Nephropathy	eGFR (normal > 60ml/min)	Result Test Date	Result Test Date	Result Test Date
	Nephropathy (Abnormal ACR, eGFR on ≥ 2 tests in 3 months)	☐ Yes ☐ No	☐ Yes ☐ No	☐ Yes ☐ No
ıthy	Dilated eye exam (type 1 annually, type 2 q1-2 years)			
Retinopathy	Retinopathy	☐ Yes ☐ No	☐ Yes ☐ No	☐ Yes ☐ No
	Severity/comments			
Neuropathy	Symptoms (Paresthesia/pain/numbness, GI symptoms, ED, diabetic foot complications)			
	Diabetic foot exam done today Record details in exam section	☐ Yes ☐ No	□ Yes □ No	☐ Yes ☐ No
	Peripheral neuropathy	☐ Yes ☐ No	☐ Yes ☐ No	☐ Yes ☐ No







		Date.	Date.	Date.
	Weight (kg)			
	ВР			
	Pulse / Rhythm			
	Diabetic foot exam			
ır.				
Physical exam & Volume Assessment	Other exam findings			
	HF Volume Assessment/Status	☐ Hypovolemic	☐ Hypovolemic	☐ Hypovolemic
	(Assessment requires combination of history, symptoms, and clinical exam findings)	Euvolemic	☐ Euvolemic	☐ Euvolemic
	and clinical exam findings)	☐ Fluid overload	☐ Fluid overload	☐ Fluid overload
	ACEI/ARB/ARNI (ACE inhibitor or ARB indicated for CV-renal benefit) (ACE inhibitor or ARB or ARNI indicated for HFrEF unless contraindicated)	Indicated: ☐ Continue ☐ Start ☐ No - not appropriate ☐ No - not tolerated ☐ No – indicated, declined ☐ No - unable to afford	Indicated: ☐ Continue ☐ Start ☐ No - not appropriate ☐ No - not tolerated ☐ No – indicated, declined ☐ No - unable to afford	Indicated: ☐ Continue ☐ Start ☐ No - not appropriate ☐ No - not tolerated ☐ No – indicated, declined ☐ No - unable to afford
	Beta blocker (Bisoprolol, carvedilol or metoprolol SR indicated for all people with HFrEF)	Indicated: ☐ Continue ☐ Start ☐ No - not appropriate ☐ No - not tolerated ☐ No – indicated, declined ☐ No - unable to afford	Indicated: ☐ Continue ☐ Start ☐ No - not appropriate ☐ No - not tolerated ☐ No – indicated, declined ☐ No - unable to afford	Indicated: ☐ Continue ☐ Start ☐ No - not appropriate ☐ No - not tolerated ☐ No – indicated, declined ☐ No - unable to afford
	MRA	Indicated: ☐ Continue ☐ Start	Indicated: ☐ Continue ☐ Start	Indicated: Continue Start
S	(Indicated as part of standard HFrEF therapy [with ACEI/ARB/ARNI, beta-blocker, +/- SGLT2I]; must be able to monitor for hyperkalemia and changes to renal function)	□ No - not appropriate □ No - not tolerated □ No – indicated, declined □ No - unable to afford	□ No - not appropriate □ No - not tolerated □ No – indicated, declined □ No - unable to afford	□ No - not appropriate □ No - not tolerated □ No – indicated, declined □ No - unable to afford
tio	SGLT2 inhibitor	Indicated: Continue Start	Indicated: Continue Start	Indicated: Continue Start
medications	(Dapagliflozin or empagliflozin indicated as part of HFrEF quadruple therapy. Dapagliflozin or empagliflozin indicated for treatment of HF with LVEF >40% (HFpEF or HFmrEF) (SGLT2) indicated for diabetic nephropathy in	□ No - not appropriate □ No - not tolerated □ No – indicated, declined	□ No - not appropriate □ No - not tolerated □ No – indicated, declined	□ No - not appropriate □ No - not tolerated □ No – indicated, declined
CVD	people with diabetes type 2)	☐ No - unable to afford	☐ No - unable to afford	☐ No - unable to afford
3	Statin (Recommended to reduce CVD risk in adults with DM1 or DM2 with any of the following features: clinical CVD, age >40 years, age >30 years and duration of DM >15 years, microvascular complications, presence of other CV risk factors in accordance with Lipid CPG)	Indicated:	Indicated: ☐ Continue ☐ Start ☐ No - not appropriate ☐ No - not tolerated ☐ No – indicated, declined ☐ No - unable to afford	Indicated: ☐ Continue ☐ Start ☐ No - not appropriate ☐ No - not tolerated ☐ No – indicated, declined ☐ No - unable to afford
	Antiplatelet agent (if established ASCVD, not for primary prevention)	☐ Not indicated ☐ Yes	☐ Not indicated ☐ Yes	☐ Not indicated ☐ Yes
	Other CV meds			
	Medication adherence/comments/notes			





		Date:	Date:	Date:
Vaccines	Vaccines reviewed, details, comments (Check EHR viewer for vaccine status)			
	Patient goals/self-management			
	Patient HF education (HF info sheet, action plan, nutrition resources)			
	Advance care planning (Discuss as needed; provide resources)			
	Referrals for education/nutrition/exercise/ cardiac rehab			
Management Plan	Referrals to medical specialists			
Manager	Assessment and management plan (Changes to medications, resources provided to patient, etc.)			
	I .			

For CDM QIP online resources/handouts, information points for aspects of care, and details of CDM QIP indicators
- https://www.ehealthsask.ca/services/CDM/Pages/default.aspx



